Bionyra Pharma announced its launch and an oversubscribed $165 million Series A financing round. The round was co-led by Jeito Capital and Sofinnova Partners. Arkin Bio, Sanofi Ventures, Sixty Degree Capital, Vives Partners, and Apollo Health Ventures also participated.
Bionyra is a clinical-stage biopharmaceutical company developing next-generation biologics for immune-mediated inflammatory diseases.
The company was seed-financed by Sofinnova Partners and co-founded with former Sanofi R&D executive Dr. Frédéric Marrache, who serves as CEO.
Bionyra is advancing mono and multispecific antibodies for diseases with significant unmet need despite existing treatment options, including atopic dermatitis and inflammatory bowel disease.
The company is launching with a pipeline of clinical and near-clinical anti-inflammatory therapies designed to combine multi-pronged biology with optimized pharmacokinetics.
Its pipeline includes BYN-002, a TL1A monoclonal antibody with half-life extension technology being developed for inflammatory bowel disease and other TL1A-relevant indications. A Phase 1 study in healthy subjects is fully enrolled.
Bionyra is also developing BYN-003, a TL1A and IL-23p19 bispecific antibody with half-life extension technology that entered the clinic in April, with a Phase 1 study underway.
The company’s pipeline also includes BYN-001, an IL-25 monoclonal antibody with half-life extension technology that is in IND-stage development for atopic dermatitis and Type 2 inflammation.
Bionyra licensed BYN-002 and BYN-003 from TrueLab Biopharmaceutical and BYN-001 from NovaRock Biotherapeutics. The company holds exclusive global rights outside of Greater China.
The company is also progressing additional preclinical assets, including some from TrueLab.
Bionyra said the financing will support the advancement of its clinical-stage pipeline and help build the company around therapies designed to deliver deeper and more durable disease control.
As part of the financing, Mehdi Ainouche of Jeito Capital, Anta Gkelou of Sofinnova Partners, Avital Adler of Arkin Bio, and Laia Crespo of Sanofi Ventures will join Bionyra’s Board of Directors.
KEY QUOTES:
“More than half of patients suffering from immune-mediated inflammatory diseases remain inadequately controlled, highlighting a significant need for better treatment options. Across our pipeline, we are selectively modulating immune pathways that are central drivers of disease in indications where current therapies remain insufficient. We have built Bionyra around assets and targets with clear therapeutic rationale, relevant biology and optimized clinical strategy to develop therapies that will deliver meaningful impact to people who don’t currently have good options.”
Dr. Frédéric Marrache, Co-Founder and CEO of Bionyra Pharma
“So many patients suffering from immune-mediated inflammatory diseases still face daily burden due to limited treatment options. Bionyra is uniquely positioned to accelerate delivery of highly promising therapies to patients through a focused and well-designed clinical development strategy aimed at rapidly generating clinical validation and addressing key unmet needs like deeper remission and alternatives for non-responders. We look forward to supporting Frédéric and the entire Bionyra team as the company reaches a pivotal stage in its development while simultaneously building a scalable pipeline in dermatology and IBD.”
Mehdi Ainouche, Partner at Jeito Capital
“When we co-founded Bionyra with Frédéric, our conviction in both the company and his leadership was grounded in his deep expertise in immune and inflammatory diseases. Today, that conviction is reflected in a $165 million oversubscribed round backed by an exceptional syndicate of investors who share our belief in this pipeline and the team behind it. Looking ahead, we are focused on advancing these programs with the aim of bringing meaningful new treatment options to patients.”
Anta Gkelou, Partner at Sofinnova Partners
